KCT0004180尚未招募未知
A phase II study of Pemetrexed after progression of platinum-based treatment for advanced thymic epithelial tumors
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 100(Year)（—）
- 性别
- All
入选标准
- •Patients have any histologically-confirmed inoperable/advanced/metastatic solid tumor (except non-small cell lung cancer) by pathology report and have received, been intolerantTET who progressed after treated with first line cisplatinplatinum containing chemotherapy (not more than two line). to, been ineligible for or refused all treatment known to confer clinical benefit.chemotherapy AND achieved objective response (SD, PR, or CR)
- •Sufficient tumor tissue to perform ALK IHC and ALK FISH is required. Both tests will be performed at Asan Medical Center.
- •Tumor with ALK IHC positive and ALK FISH positive = 1 unidimensionally measurable lesion as defined by RECIST v1.1
- •After ALK test by Ventana IHC (Appendix 2), patient samples will also be tested by FISH Vysis® ALK Break Apart FISH Probe Kit (Abbott).
- •Age =18 years old
- •Lift expectancy of at least 12 weeks
- •ECOG PS of 0-2
- •Adequate hematologic function
- •Platelet count = 100 x 109/L
- •ANC =1500 cells/uL
- •Hemoglobin = 9.0 g/dL
- •Adequate renal function: An estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease equation of at least 45 mL/min/1.73 m2
- •Patients must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment.
- •Adequate hematologic function
- •Measurable disease (by RECIST v1.1) prior to the administration of study treatment
- •Prior brain or leptomeningeal metastases allowed if asymptomatic (e.g., diagnosed incidentally at study baseline). Asymptomatic CNS lesions might be treated at the discretion of the investigator as per local clinical practice. If patients have neurological symptoms or signs due to CNS metastasis, patients need to complete whole brain radiation or gamma knife irradiation treatment. In all cases, radiation treatment must be completed at least 14 days before enrollment and patients must be clinically stable.
- •For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment.
- •Able and willing to provide written informed consent prior to performing any study-related procedures
排除标准
- •?TET with neuroendocrine feature or small cell histology
- •?Prior participation in a study investigating pemetrexed or practical treatment with pemetrexed
- •?Serious cardiac condition, such as myocardial infarction, angina, or heart disease
- •?Patients with a previous malignancy within the past 3 years are excluded (other than curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, or any cured cancer that is considered to have no impact in PFS and OS for the current malignancy).
- •? Liver disease characterized by:
- •–ALT or AST > 3 × ULN (= 5 × ULN for patients with concurrent liver metastasis) confirmed on two consecutive measurements
- •–Impaired excretory function (e.g., hyperbilirubinemia) or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, and bleeding from esophageal varices
- •?National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (version 4.0) Grade 3 or higher toxicities due to any prior therapy such as radiotherapy (excluding alopecia), which have not shown improvement and are strictly considered to interfere with current study medication
- •?History of organ transplant
- •?Pregnant or lactating women
- •?Known HIV positivity or AIDS-related illness
研究者
相似试验
招募中
不适用
Study of pemetrexed in previously-treated patients with advanced squamous cell lung carcinoma having low level of TSKCT0003518CC Hospital32
招募中
2 期
A randomized phase II study of pemetrexed versus pemetrexed plus carboplatin in chemotherapy-naive elderly patients with IIIB/IV non-squamous non-small cell lung cancer.JPRN-UMIN000006129Division of Medical Oncology and Molecular Respirology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University60
进行中（未招募）
不适用
A phase 2 study of Pemetrexed versus Pemetrexed + Erlotinib in second line Treatment for NSCLCPatients who have histologically or cytologically documented diagnosis of Non Small Cell Lung Cancer (Stage IIIA, IIIB or IV at entry), with progressive disease after treatment with 1 prior chemotherapy regimen, who are considered for second line therapy.MedDRA version: 8.1Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSEUCTR2006-005118-11-ATEli lilly and Company Limited150
进行中（未招募）
不适用
A phase 2 study of Pemetrexed versus Pemetrexed + Erlotinib in second line Treatment for NSCLCEUCTR2006-005118-11-HUEli lilly and Company Limited150
进行中（未招募）
不适用
A randomized phase II trial of pemetrexed with or without PF-3512676 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of one prior chemotherapy regimen for advanced diseaseTreatment of patients with locally advanced or metastatic non-small lung cancer (NSLC) after failure of one prior chemotherapy regimen for advanced diseaseMedDRA version: MedLevel: VTcClassification code 10061873EUCTR2006-001588-52-DEPfizer Pharma GmbH130